RVKA Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.89M
Enterprise Value€1.89
Total Cash (Recent Filing)€2.64M
Total Debt (Recent Filing)€125.00K
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding237,950,650
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.63
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageConservative leverage materially reduces financial risk and interest burden, giving Omega greater flexibility to withstand operating volatility. A lightly levered balance sheet can also preserve capacity for working capital, restructuring, or targeted investment while the company works to restore profitability.
Resilient Gross MarginsSustained gross margins indicate that Omega’s diagnostic products retain meaningful value after direct production costs, even during a period of severe losses. This provides a potentially solid foundation for recovery if operating costs, revenue scale, and commercial execution improve.
Broad IVD Product PlatformExposure across rapid tests, laboratory assays, and related diagnostic components gives Omega several ways to serve healthcare and laboratory customers. This breadth may support customer relevance and product development flexibility across different testing workflows over time.
Bears Say
Revenue ContractionThe return to revenue contraction after the 2024 rebound suggests that demand and commercial momentum have not yet become consistent. Shrinking sales can reduce operating leverage, make fixed costs harder to absorb, and limit the resources available for product investment and growth.
Severe Profitability VolatilityThe sharp swing from strong profitability to heavy losses shows that gross margin is not translating reliably into operating or net earnings. Such volatility weakens earnings visibility, can erode equity, and makes sustained self-funded expansion more difficult over the coming quarters.
Renewed Cash BurnThe reversal from positive operating and free cash flow in 2024 to substantial cash burn in 2026 indicates that the business is not consistently funding itself. Persistent negative cash generation can constrain reinvestment and increase reliance on external funding or balance-sheet resources.
Omega Diagnostics News
RVKA FAQ
What was Omega Diagnostics Group PLC’s price range in the past 12 months?
Omega Diagnostics Group PLC lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Omega Diagnostics Group PLC’s market cap?
Omega Diagnostics Group PLC’s market cap is €3.89M.
When is Omega Diagnostics Group PLC’s upcoming earnings report date?
Omega Diagnostics Group PLC’s upcoming earnings report date is Nov 19, 2026 which is in 63 days.
How were Omega Diagnostics Group PLC’s earnings last quarter?
Omega Diagnostics Group PLC released its earnings results on Sep 08, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of -€0.001 by -€0.01.
Is Omega Diagnostics Group PLC overvalued?
According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued.
Does Omega Diagnostics Group PLC pay dividends?
Omega Diagnostics Group PLC does not currently pay dividends.
What is Omega Diagnostics Group PLC’s EPS estimate?
Omega Diagnostics Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Omega Diagnostics Group PLC have?
Omega Diagnostics Group PLC has 237,950,650 shares outstanding.
What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?
Omega Diagnostics Group PLC reported an EPS of -€0.012 in its last earnings report, missing expectations of -€0.001. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?
Currently, no hedge funds are holding shares in DE:RVKA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Omega Diagnostics Group PLC
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
Technical Analysis
Advanced Medical Solutions
―
EKF Diagnostics Holdings
―
IXICO plc
―
Tristel
―
Abingdon Health PLC
―